Journal article

Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies

Katharina Nimptsch, Mingyang Song, Krasimira Aleksandrova, Michail Katsoulis, Heinz Freisling, Mazda Jenab, Marc J Gunter, Konstantinos K Tsilidis, Elisabete Weiderpass, H Bas Bueno-De-Mesquita, Dawn Q Chong, Majken K Jensen, Chunsen Wu, Kim Overvad, Tilman Kuehn, Myrto Barrdahl, Olle Melander, Karin Jirstrom, Petra H Peeters, Sabina Sieri Show all

European Journal of Epidemiology | SPRINGER | Published : 2017


Awarded by Health Research Fund (FIS)

Awarded by Regional Government of Andalucia (Spain)

Awarded by Regional Government of Asturias (Spain)

Awarded by Regional Government of Basque Country (Spain)

Awarded by Regional Government of Murcia, (Spain)

Awarded by Regional Government of Navarra, ISCIII RETIC (Spain)

Awarded by Cancer Research UK (United Kingdom)

Awarded by Medical Research Council (United Kingdom)

Awarded by U.S. NIH

Funding Acknowledgements

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Santeet de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada; PI13/01162 to EPIC-Murcia), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236), and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Measurement of biomarkers in EPIC was partly supported by World Cancer Research Fund International and Wereld Kanker Onderzoek Fonds (WCRF NL). The research based on the Nurses' Health Study and the Health Professional Follow-up Study are financially supported by U.S. NIH grants [P01 CA87969, UM1 CA186107, R01 CA49449 (to NHS), P01 CA55075, UM1 CA167552 (to HPFS), P50 CA127003 (to C.S. Fuchs), R01 CA151993, R35 CA197735 (to S. Ogino), K24 DK098311 and R01 CA137178 (to A.T. Chan)]. A.T. Chan is a Damon Runyon Clinical Investigator. We would like to thank the participants and staff of the Nurses' Health Study and Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.